Summary of Clinical Use

Pacibekitug was originally progressed by Pfizer as a clinical candidate for the treatment of chronic inflammatory diseases. It has subsequently been re-positioned for atherosclerotic cardiovascular disease (by Tourmaline Bio and now Novartis), since inflammation is a signficant driver of atherosclerosis.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT06088979	A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease	Phase 2 Interventional	Tourmaline Bio, Inc.
NCT06362759	A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP	Phase 2 Interventional	Tourmaline Bio, Inc.
NCT00838565	Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis	Phase 1 Interventional	Pfizer
NCT01405196	Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus	Phase 2 Interventional	Pfizer		4
NCT01287897	A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy	Phase 2 Interventional	Pfizer		1